Introduction {#Sec1}
============

HbA~1c~ is an established means of monitoring average blood glucose levels and a surrogate marker of the effect of glucose-lowering interventions \[[@CR1]\]. It is highly associated with the risk for diabetes-related complications, in particular those of microvascular origin \[[@CR2]--[@CR5]\]. Although HbA~1c~ is almost universally accepted to guide and monitor diabetes treatment, its use in clinical practice has arguable limitations. There is a proposed inter-individual variation in the propensity for glycation, in both healthy individuals and those with diabetes \[[@CR6]--[@CR13]\], limiting the use of HbA~1c~ as a one-size-fits-all measurement. Moreover, the value of HbA~1c~ as a surrogate endpoint was questioned by the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, where HbA~1c~ lowering may have had detrimental effects on the risk of premature mortality \[[@CR14]\]. Therefore, 'the lower the better' may not universally hold for HbA~1c~, and additional (bio)markers might be useful to individualise treatment targets and risk prediction \[[@CR15]\].

The haemoglobin glycation index (HGI) quantifies the variation in the relation between HbA~1c~ and the plasma glucose concentration \[[@CR16]\]. For any individual within a study population, HGI is defined as the difference between the observed HbA~1c~ and the fitted value from a simple linear model that predicts HbA~1c~ from the fasting plasma glucose (FPG) concentration, i.e. the residual from the fitted linear regression line. In previous studies, HGI was normally distributed, stable over time and consistent over a wide range of blood glucose concentrations \[[@CR17]--[@CR20]\]. In an analysis in individuals with type 1 diabetes in the DCCT, a high HGI was associated with the risk for and progression of retino- and nephropathy \[[@CR21]\]. In an analysis of the ACCORD trial, only participants in the highest HGI third were at higher risk for mortality and those with high HGI showed no benefit on cardiovascular outcomes after intensive glucose lowering, in contrast to participants with a low or intermediate HGI \[[@CR16]\]. The use of HGI is not without controversy, as in the DCCT population it was shown that the effect of HGI on microvascular complications disappeared after adjustment for the effect of HbA~1c~ \[[@CR22]\]. However, the use of HbA~1c~ in type 1 diabetes is undisputed, whereas in individuals with type 2 diabetes, HbA~1c~ seems to have shortcomings, as demonstrated by the ACCORD trial.

The aim of this study was to assess whether HGI is a predictor of adverse outcomes of intensive glucose-lowering therapy and a predictor of diabetes-related complications in the cohort of individuals with type 2 diabetes recruited for the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial ([ClinicalTrials.gov](http://clinicaltrials.gov) registration no. NCT00145925) \[[@CR23]\]. Additionally, we aimed to compare the predictive values of HGI and HbA~1c~ to assess the possible added value of HGI beyond HbA~1c~.

Methods {#Sec2}
=======

ADVANCE trial {#Sec3}
-------------

In the ADVANCE trial, 11,140 individuals with type 2 diabetes and a history of, or a risk factor for, vascular disease were randomised in a factorial design between two BP-lowering strategies and two glucose-lowering strategies \[[@CR24]\]. Glucose-lowering treatment was either standard (based on local guidelines) or intensive, starting with gliclazide (30--120 mg daily, modified release) and adding other medication as necessary (based on the study protocol and discretion of the treating physician) to achieve a HbA~1c~ level of ≤48 mmol/mol (≤6.5%). Primary endpoints were a composite of major macro- and microvascular events. Study participants were, on average, 66 years old, with a mean diabetes duration of 8 years and a mean baseline HbA~1c~ of 59 mmol/mol (7.5%). After a follow-up of 5 years, mean HbA~1c~ was 48 mmol/mol (6.5%) in the intensively treated group vs 56 mmol/mol (7.3%) in the standard group. Intensive glucose-lowering treatment reduced the combination of macro- and microvascular events, mainly due to a 20% reduction in nephropathy, at the cost of an 86% increase in the risk of severe hypoglycaemia.

Present study {#Sec4}
-------------

### HGI {#FPar1}

We excluded 57 individuals with missing baseline HbA~1c~ (*n* = 54) or baseline FPG (*n* = 3). For the 11,083 remaining individuals, we fitted a linear regression. The linear regression equation describing the relation between baseline HbA~1c~ and FPG in our population was HbA~1c~ (%) = 4.5 + 0.356 × FPG (mmol/l) (*r*^2^ = 0.40, Fig. [1](#Fig1){ref-type="fig"}a). Results from simple linear regression were comparable with a cubic spline model, so we chose the simpler linear model. We derived predicted HbA~1c~ by inserting FPG values into this regression equation. Baseline HGI was calculated by subtracting predicted HbA~1c~ from observed HbA~1c~ (equalling the residual from the regression line, Fig. [1](#Fig1){ref-type="fig"}b). In this way, individuals with high HGI will have a higher measured HbA~1c~ than anticipated from the FPG value. In accordance with existing literature, we divided the population in three equally sized HGI groups (low, intermediate and high). This study was conducted according to the principles of the declaration of Helsinki \[[@CR25]\] and in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO). All participants provided written informed consent for the original study.Fig. 1 **(a)** Regression of FPG on HbA~1c~. The dotted line represents the simple linear regression line of the equation: HbA~1c~ (%) = 4.5 + 0.356 × FPG (mmol/l), *r*^2^ = 0.40. **(b)** Plot of the residuals (HGI) vs the fitted (predicted HbA~1c~) values (*p*=1.00). To convert values for HbA~1c~ in % into mmol/mol, subtract 2.15 and multiply by 10.929

### Outcomes {#FPar2}

We analysed four predefined outcome measures: (1) major macrovascular events, defined as death from cardiovascular cause, non-fatal myocardial infarction or non-fatal stroke; (2) major microvascular events, defined as new or worsening nephropathy or retinopathy; (3) total mortality; and (4) severe hypoglycaemia. Severe hypoglycaemia was defined as transient dysfunction of the central nervous system that could not be self-treated.

### Statistical analysis {#FPar3}

We compared baseline characteristics between the low, intermediate and high HGI groups using ANOVA or Kruskal--Wallis tests for continuous variables, depending on the distribution, and *χ*^2^ tests for categorical variables. We used Cox proportional hazard regression models to analyse the association between baseline HGI and time to event for all four outcomes, with adjustment for covariates. We studied separately: (1) the treatment-modifying effect of HGI; and (2) the effect of HGI independent of treatment allocation---the first to make a comparison with the results from the ACCORD reanalysis, the latter as it seems more relevant for use in clinical practice where individuals will undergo variable treatment regimens. To assess whether HGI was better than time-matched (baseline) HbA~1c~ we added HbA~1c~ as a covariate to our models and used HbA~1c~ instead of HGI as predicting variable to compare the effect on outcomes.

### Treatment-modifying effect of HGI {#FPar4}

We investigated the effect of intensive glucose control on outcomes across HGI groups, by adding the interaction term between HGI group and treatment allocation (intensive or standard glucose-lowering therapy) to the model with HGI and treatment. We adjusted the model for age, sex, ethnic origin (Asian or non-Asian), BMI, duration of type 2 diabetes, history of macro- and microvascular events, current drinking and smoking habits, use of glucose-lowering medication, use of BP-lowering drugs, systolic and diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDL- and total cholesterol and triacylglycerol. We added baseline HbA~1c~ to the before-mentioned covariates in a separate analysis. Finally, we assessed the associations between HbA~1c~ (instead of HGI) as the exposure variable and outcomes, adjusted for the same covariates and studied the interaction between treatment and HbA~1c~.

### Effect of HGI independent of treatment allocation {#FPar5}

We assessed the association between HGI and outcomes, irrespective of treatment, for the low, intermediate and high HGI group, as well as for HGI as a continuous variable. The low HGI group served as the reference group in the comparison. We adjusted for the identical set of standard covariates (with and without HbA~1c~). Again, we assessed the associations between HbA~1c~ (instead of HGI) as the exposure variable and outcomes, adjusted for the same covariates.

As only 1.5% of data were missing, no imputation was carried out. Significance levels were set at a *p* \< 0.05. Statistical analyses were performed using SAS Enterprise Guide 7.1 (SAS STAT 9.4; SAS Institute, Cary, NC, USA).

Results {#Sec5}
=======

In this population, HGI showed a normal distribution, ranging from −6.46 to 8.99, with a mean of 0 (SD 1.20). When dividing the study population into thirds, HGI cut-off points were ≤−0.53 for the low, −0.52 to 0.28 for the intermediate and ≥0.29 for the high HGI group. Mean baseline HGI was −1.14 (SD 0.57) in the low, −0.14 (SD 0.23) in the intermediate and 1.29 (SD 0.99) in the high HGI group (Table [1](#Tab1){ref-type="table"}).Table 1 Baseline characteristics of individuals by HGI groupCharacteristicLow HGI, *n*=3694Intermediate HGI, *n*=3696High HGI, *n*=3693*p* value^a^HGI (%)−1.14 ± 0.57−0.14 ± 0.231.29 ± 0.99HbA~1c~ (mmol/mol)45.0 (40.0--52.0)54.0 (49.0--60.0)69.0 (61.0--81.0)\<0.0001HbA~1c~ (%)6.30 (5.80--6.90)7.06 (6.60--7.60)8.50 (7.71--9.60)\<0.0001FPG (mmol/l)8.10 (6.83--10.00)7.60 (6.40--9.10)8.10 (6.60--10.20)\<0.0001Age (years)65.89 ± 6.3866.28 ± 6.4365.18 ± 6.32\<0.0001Female sex1543 (41.8)1524 (41.2)1635 (44.3)0.019BMI (kg/m^2^)28.36 ± 5.1028.61 ± 5.2628.05 ± 5.19\<0.0001Diabetes duration (years)6 (2--11)6 (3--11)8 (4--12)\<0.0001Asian ethnicity1234 (33.4)1233 (33.4)1750 (47.4)\<0.0001Current smoker499 (13.5)578 (15.6)598 (16.2)0.003Current drinker1298 (35.1)1245 (33.7)835 (22.6)\<0.0001Systolic BP (mmHg)145.56 ± 21.56144.81 ± 21.13144.67 ± 21.900.164Diastolic BP (mmHg)80.87 ± 10.8780.49 ± 10.9380.54 ± 10.970.260eGFR (ml min^−1^ \[1.73 m\]^−2^)74.54 (62.53--87.60)74.73 (62.25--88.17)75.25 (61.37--89.88)0.527HDL-cholesterol (mmol/l)1.28 ± 0.371.25 ± 0.341.24 ± 0.34\<0.0001LDL-cholesterol (mmol/l)3.11 ± 1.043.06 ± 1.003.16 ± 1.050.0001Total cholesterol (mmol/l)5.20 ± 1.195.14 ± 1.125.25 ± 1.260.001Triacylglycerol (mmol/l)1.60 (1.16--2.30)1.60 (1.19--2.30)1.70 (1.20--2.40)0.001Glucose-lowering medication3256 (88.1)3326 (90.0)3496 (94.7)\<0.0001Insulin42 (1.1)43 (1.2)70 (1.9)0.007BP-lowering medication2865 (77.6)2773 (75.0)2694 (72.9)\<0.0001Past microvascular event315 (8.5)357 (9.7)481 (13.0)\<0.0001Past macrovascular event1187 (32.1)1179 (31.9)1206 (32.7)0.776Values are presented as mean ± SD, median (IQR) or proportion (%)^a^Two-sided *p* values for overall differences between HGI groups from ANOVA, Kruskal--Wallis or *χ*^2^ tests

There were some significant differences in baseline characteristics between the HGI groups (Table [1](#Tab1){ref-type="table"}). Individuals in the high HGI group had the longest duration of diabetes and a higher proportion used glucose-lowering medication. More of those in the high HGI group were smokers, but fewer consumed alcohol. The prevalence of previous microvascular events was highest in the high HGI group. Almost half of the individuals in the high HGI group were of Asian origin, in contrast to a third in the low and intermediate group. HbA~1c~ levels increased from low to high HGI group and FPG was lowest in the intermediate HGI group.

Treatment-modifying effect of HGI {#Sec41}
---------------------------------

Table [2](#Tab2){ref-type="table"} shows the adjusted HRs based on HGI group and treatment allocation (intensive or standard glucose-lowering therapy). The effect of treatment allocation on macro- and microvascular complications was similar across the three HGI groups. However, the effect of intensive therapy on mortality risk differed between HGI groups (*p* for interaction = 0.011). In the high HGI group the mortality risk was significantly lower with intensive therapy (adjusted HR 0.74 \[95% CI 0.61, 0.91\]; *p* = 0.003), whereas intensive treatment did not diminish risk for mortality in the low and intermediate groups. This effect remained after additional adjustment for baseline HbA~1c~ level (electronic supplementary material (ESM) Table [1](#MOESM1){ref-type="media"}). With regard to severe hypoglycaemia, absolute rates increased progressively as HGI rose, regardless of whether individuals received intensive or standard treatment. The effect of intensive treatment on the risk for severe hypoglycaemia was not different between HGI thirds, as indicated by the non-significant *p* value for interaction (0.228). To compare the predictive value of HGI with HbA~1c~, we assessed the interaction between treatment and HbA~1c~ groups using the same multivariable model (ESM Table [2](#MOESM1){ref-type="media"}). Here, there was no difference in effect of intensive treatment on mortality risk across the three HbA~1c~ groups (*p* for interaction = 0.530). Individuals with intermediate and high HbA~1c~ were at greater risk for severe hypoglycaemia when intensively treated, contrary to individuals with low HGI.Table 2 Multivariable Cox proportional hazard regression analysis for major macrovascular events, major microvascular events, total mortality and severe hypoglycaemia predicted by treatment and HGI groupIntensive treatmentStandard treatmentAdjusted HR^e^*p* value for interaction^f^Events by HGI groupAt risk (*n*)Events (*n*)%^d^At risk (*n*)Events (*n*)%^d^Estimate (95% CI)*p* valueMajor macrovascular events^a^  Overall55425555.055415875.30.95 (0.84, 1.07)0.4030.124  Low HGI18731804.918211644.41.12 (0.91, 1.39)0.297  Intermediate HGI18291674.518671784.80.92 (0.74, 1.14)0.436  High HGI18402085.618532456.60.84 (0.69, 1.01)0.059Major microvascular events^b^  Overall55425264.755416035.40.87 (0.77, 0.99)0.0290.845  Low HGI18731413.818211594.30.84 (0.67, 1.06)0.136  Intermediate HGI18291484.018671784.80.87 (0.70, 1.08)0.216  High HGI18402376.418532667.20.91 (0.77, 1.09)0.314Total mortality  Overall55424944.555415314.80.95 (0.84, 1.08)0.4200.011  Low HGI18731604.318211373.71.17 (0.93, 1.47)0.181  Intermediate HGI18291604.318671624.40.98 (0.79, 1.23)0.887  High HGI18401744.718532326.30.74 (0.61, 0.91)0.003Severe hypoglycaemia^c^  Overall55421491.35541810.71.82 (1.38, 2.40)\<0.00010.228  Low HGI1873340.91821240.61.34 (0.79, 2.27)0.276  Intermediate HGI1829491.31867280.81.82 (1.14, 2.90)0.012  High HGI1840661.81853290.82.45 (1.57, 3.85)\<0.0001^a^Major macrovascular events were defined as death from a cardiovascular cause, non-fatal myocardial infarction or stroke^b^Major microvascular events were defined as new or worsening nephro- or retinopathy^c^Severe hypoglycaemic episodes were defined as transient dysfunction of the central nervous system with the inability to treat oneself^d^Percentage of events respective to the total cohort (overall, *n=*11,083; low HGI, *n*=3694; intermediate HGI, *n*=3696; high HGI, *n*=3693)^e^Model was adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration of type 2 diabetes, history of macro- and microvascular events, current drinking and smoking, use of glucose-lowering drugs, use of BP-lowering drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDL- and total cholesterol, triacylglycerol^f^*p* value for interaction between treatment effect and HGI group

Effect of HGI independent of treatment allocation {#Sec42}
-------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows HRs for outcomes by HGI group irrespective of treatment allocation, with the low HGI group as reference group. In the multivariable analysis, individuals in the high HGI group had a significantly higher risk for major macrovascular events, compared with the low HGI group (HR 1.26 \[95% CI 1.09, 1.46\]; *p* = 0.002). Further, the risk for major microvascular events and mortality was also higher in the high HGI group compared with the low HGI group (HR 1.46 \[95% CI 1.26, 1.69\], *p* \< 0.0001 and HR 1.36 \[95% CI 1.17, 1.59\], *p* \< 0.0001, respectively). The risk of severe hypoglycaemia did not differ between HGI groups. The effect of HGI on these complications disappeared after additional adjustment for HbA~1c~ (ESM Table [3](#MOESM1){ref-type="media"}). Again, we assessed the association between HbA~1c~ groups and adverse outcomes using the same multivariable model (ESM Table [4](#MOESM1){ref-type="media"}). Likewise, the high HbA~1c~ group had a higher risk for macro- and microvascular complications and mortality compared with the low HbA~1c~ group. HRs exceeded those seen for HGI. HbA~1c~ was not associated with the risk of severe hypoglycaemia.Table 3 Cox proportional hazard regression analysis for major macrovascular events, major microvascular events, total mortality and severe hypoglycaemia predicted by HGI group (using the low group as a reference)Unadjusted HRAdjusted HR^d^Events by HGI groupAt risk (*n*)Events (*n*)%Estimate 95% CI*p* value (vs low)Estimate 95% CI*p* value (vs low)Major macrovascular events^a^  Overall11,083114210.3  Low HGI36943449.3  Intermediate HGI36963459.31.00 (0.86, 1.16)0.9890.97 (0.84, 1.13)0.738  High HGI369345312.31.35 (1.17, 1.55)\<0.00011.26 (1.09, 1.46)0.002Major microvascular events^b^  Overall11,083112910.2  Low HGI36943008.1  Intermediate HGI36963268.81.09 (0.93, 1.27)0.2861.09 (0.93, 1.27)0.306  High HGI369350313.61.77 (1.53, 2.04)\<0.00011.46 (1.26, 1.69)\<0.0001Total mortality  Overall11,08310259.2  Low HGI36942978.0  Intermediate HGI36963228.71.09 (0.93, 1.27)0.3001.01 (0.86, 1.19)0.865  High HGI369340611.01.39 (1.19, 1.61)\<0.00011.36 (1.17, 1.59)\<0.0001Severe hypoglycaemia^c^  Overall11,0832302.1  Low HGI3694581.6  Intermediate HGI3696772.11.30 (0.91, 1.84)0.1441.25 (0.88, 1.77)0.219  High HGI3693952.61.56 (1.11, 2.20)0.0101.33 (0.94, 1.89)0.110^a^Major macrovascular events were defined as death from a cardiovascular cause, non-fatal myocardial infarction or stroke^b^Major microvascular events were defined as new or worsening nephro- or retinopathy^c^Severe hypoglycaemic episodes were defined as transient dysfunction of the central nervous system with the inability to treat oneself^d^Model was adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration of type 2 diabetes, history of macro- and microvascular events, current drinking and smoking, use of glucose-lowering drugs, use of BP-lowering drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDL- and total cholesterol, triacylglycerol

When we considered HGI as a continuous variable, every 1 SD (=1.20 HGI) increase resulted in a 14% risk increase for microvascular complications, a 17% risk increase for macrovascular complications and a 16% risk increase for mortality (*p* \< 0.0001) (Fig. [2](#Fig2){ref-type="fig"}). Continuous HGI was not associated with severe hypoglycaemia (HR 1.10 \[95% CI 0.97, 1.25\]; *p* = 0.123). Continuous HbA~1c~ (1 SD = 1.56% HbA~1c~) was a stronger predictor for the risk of microvascular events (HR 1.19 \[95% CI 1.13, 1.26\]; *p* \< 0.0001), macrovascular events (HR 1.31 \[95% CI 1.24, 1.38\]; *p* \< 0.0001) and mortality (HR 1.14 \[95% CI 1.14, 1.28\]; *p* \< 0.0001) than HGI.Fig. 2 Multivariable Cox proportional hazard regression analysis for major macrovascular events, major microvascular events, total mortality and severe hypoglycaemia predicted by continuous HGI and HbA~1c~ per SD increase (1 SD of HGI is 1.20. 1 SD of HbA~1c~ is 1.56%). Major macrovascular events were defined as death from a cardiovascular cause, non-fatal myocardial infarction or stroke. Major microvascular events were defined as new or worsening nephro- or retinopathy. Severe hypoglycaemic episodes were defined as transient dysfunction of the central nervous system with the inability to treat oneself. Model was adjusted for age, sex, ethnic origin (Asian vs non-Asian), BMI, duration of type 2 diabetes, history of macro- and microvascular events, current drinking and smoking, use of glucose-lowering drugs, use of BP-lowering drugs, systolic BP, diastolic BP, haemoglobin, renal function (eGFR), LDL-, HDL- and total cholesterol, triacylglycerol. Diamonds, HGI; circles, HbA~1c~

Discussion {#Sec6}
==========

With this analysis of the ADVANCE trial we showed that HGI predicts diabetes-related complications, but no better than HbA~1c.~ Irrespective of treatment allocation, the high HGI group (i.e. individuals with higher HbA~1c~ levels than would be expected for their given fasting glucose levels) was at higher risk for macro- and microvascular complications and mortality compared with the low HGI group. Every SD increase in HGI gave a significant 14--17% risk increase for these three outcomes. Hypothetically, this could be explained by a higher propensity for glycation of membrane proteins and lipids other than haemoglobin, with these glycation products leading to microvascular complications and atherogenesis. This effect disappeared after additional adjustment for HbA~1c~, which is in line with results on the effect of HGI in individuals with type 1 diabetes in the DCCT \[[@CR22]\]. However, this might be considered over-adjustment, as HGI is so strongly related to HbA~1c~ (HGI is HbA~1c~ corrected for FPG). Therefore, we separately assessed the effect of HbA~1c~ on outcomes using the same model and found that HbA~1c~ was just as strong or even stronger for predicting complications in this cohort of individuals with type 2 diabetes. To our knowledge, this is the first time the predictive value of HGI has been compared with that of HbA~1c~ in this way. As HbA~1c~ does not need a population regression equation as does HGI, this makes HbA~1c~ more straightforward and convenient to use.

In our study, intensive treatment carried a lower risk for mortality in individuals with a high HGI, whereas it had no effect on mortality in individuals with a low or intermediate HGI. Thus, a high HGI identified a group of people who benefitted most from intensive HbA~1c~-lowering treatment in terms of mortality. This finding remained after additional correction for baseline HbA~1c~, but was not replicated by using HbA~1c~ as the predicting variable, as we found no interaction between treatment and HbA~1c~ groups. Overall, the estimates for the effect of intensive treatment as shown in Table [2](#Tab2){ref-type="table"} remained unchanged after additional adjustment for HbA~1c~ (ESM Table [1](#MOESM1){ref-type="media"}), which is not surprising given that HGI is just a linear function of HbA~1c~ and FPG (i.e. it is HbA~1c~ -- (a + b × FPG), where a and b are regression coefficients). The above directly opposes the results of an analysis of the ACCORD trial, where intensive treatment was associated with a significantly higher, instead of lower, risk for mortality in participants with a high HGI \[[@CR16]\]. Thus, the hypothesis put forward that a high HGI results in more complications due to more intensive treatment to lower HbA~1c~ than is necessary to lower plasma glucose is not supported by our study.

The inconsistency between the effect of HGI on outcomes in these two large outcome studies might be explained by important differences between ACCORD and ADVANCE. First, glucose-treatment strategies were different, although both took HbA~1c~ as predominant measure of glycaemia and both took glucose into account. Glycaemic treatment in ACCORD was intensified when HbA~1c~ level was ≥42 mmol/mol (≥6%) or when \>50% of the self-monitored pre- or 2 h post-meal capillary glucose values were above a certain threshold \[[@CR26]\].The treatment algorithm of the ADVANCE trial took discrepancies between HbA~1c~ levels and blood glucose values into account simultaneously \[[@CR23]\]. When HbA~1c~ level was \>47 mmol/mol (\>6.5%) but fasting glucose was relatively low, mealtime interventions were optimised and the reliability of the tests was checked. Also ACCORD had participants who started with a higher HbA~1c~ and had a lower target HbA~1c~ in the intensive group. Further, 30% more individuals under intensive treatment received insulin in ACCORD compared with ADVANCE \[[@CR5]\]. This is in agreement with the observation that FPG was treated more aggressively in ACCORD, with a decrease of 3.3 mmol/l from baseline to end of trial, compared with 1.9 mmol/l in ADVANCE. Moreover, in ADVANCE all participants received a sulfonylurea derivative at the start, while in ACCORD thiazolidinedione treatment was frequently used. The additional treatments differed between studies (i.e. use of aspirin and statins was substantially higher in ACCORD). Second, ACCORD was terminated prematurely, limiting the follow-up, and potentially misrepresenting estimates (no adjustment to standard errors was made for early stopping). Third, ADVANCE and ACCORD were discordant in the major findings, including mortality. In ACCORD, mortality rates were significantly higher in the intervention arm compared with the control arm \[[@CR14]\], whereas in ADVANCE there were no significant differences in mortality between arms \[[@CR23]\]. Post hoc, it was shown that intensively treated ACCORD participants with a high average on-treatment HbA~1c~ (\>53 mmol/mol \[\>7%\]) were at greater risk for mortality than intensively treated participants with average HbA~1c~ \<53 mmol/mol (\<7%) or standard-treated individuals with average HbA~1c~ \>53 mmol/mol (\>7%) \[[@CR27]\]. The number of individuals experiencing severe hypoglycaemia was significantly higher with intensive treatment in both studies, but the event rates per person-year were higher in the ACCORD trial (3.5% per year with intensive treatment vs 1.0% per year in the control arm), whereas in ADVANCE rates were 0.7% per year in intensive treatment vs 0.4% per year in the control arm. We found no observable difference in the effect of HGI on severe hypoglycaemia due to intensive treatment, although the absolute rates and adjusted hazard ratios increased as HGI rose. With regard to HbA~1c~, individuals with intermediate and high HbA~1c~ were at greater risk for severe hypoglycaemia when intensively treated compared with individuals with low HbA~1c~, a finding consistent with previous literature \[[@CR28]\].

Baseline characteristics of individuals with high HGI accorded with previous studies \[[@CR16], [@CR29]\]. The ethnic differences (i.e. more Asians in the high HGI group) are consistent with the observation that ethnicity influences the haemoglobin glycation, with, in general, relative higher HbA~1c~ levels in non-whites \[[@CR17], [@CR30]--[@CR33]\]. However, regression equations in Asian (HbA~1c~ = 4.6 + 0.373 × FPG, *r*^2^ = 0.41) and non-Asian (HbA~1c~ = 4.5 + 0.340 × FPG, *r*^2^ = 0.40) participants were very similar. The combination of a slightly younger age, longer duration of diabetes (on average 2 years), more use of glucose-lowering medication and higher rates of microvascular complications suggests that individuals with high HGI might have a form of diabetes that is more difficult to treat. This in itself can be the cause of diabetes-related complications, but there is also potential for confounding, as these characteristics could well be explained by the higher HbA~1c~ levels in individuals with high HGI \[[@CR22]\]. The HGI concept is based on the proposed inter-individual variation in haemoglobin glycation, while an adequate method for measuring glycation rate is lacking. Erythrocyte lifespan is a major determinant of the variation in haemoglobin glycation and subtle natural variation in senescence of erythrocytes is complex to quantify \[[@CR34], [@CR35]\]. To our knowledge, there are no studies focusing on the pathophysiological mechanism explaining both the biological variation in haemoglobin glycation as well as the reason for the possible increased risk for complications associated with higher glycation rates. This study was limited by a single FPG measurement to determine the relationship with HbA~1c~, so we could not take diurnal changes in plasma glucose into account. A measure of average glucose would have been preferred, but was not available in our data and might not be in clinical practice where individuals often use oral glucose-lowering medication only. The DCCT used seven-point glucose profiles to assess HGI \[[@CR21]\], while ACCORD used FPG only \[[@CR16]\].

In conclusion, we found that HGI predicted macro- and microvascular complications and mortality, but was no better than HbA~1c~, which was a stronger predictor for these outcomes. Moreover, HbA~1c~ is simpler than HGI. High HGI does predict risk for mortality with intensive treatment, but results are the opposite of those from ACCORD. Bringing all this together, the evidence does not support the clinical relevance and usefulness of HGI above HbA~1c~.
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ACCORD

:   Action to Control Cardiovascular Risk in Diabetes

ADVANCE

:   Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation

FPG

:   Fasting plasma glucose

HGI

:   Haemoglobin glycation index
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